您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Necrostatin 2 R-isomer
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Necrostatin 2 R-isomer
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Necrostatin 2 R-isomer图片
CAS NO:852391-19-6
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 277.71
Formula C13H12ClN3O2
CAS No. 852391-15-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 10 mM
Water: N/A
Ethanol: N/A
Chemical Name 5-[(7-chloro-1H-indol-3-yl)methyl]-3-methyl-2,4-imidazolidinedione
Synonyms Necrostatin-2 R-isomer; Necrostatin 2; (±)-Necrostatin-2; Necrostatin-2 racemate; 7-Cl-O-Nec-1; Nec-1S;
SMILES Code O=C1N(C)C(C(CC2=CNC3=C2C=CC=C3Cl)N1)=O
实验参考方法
In Vitro

In vitro activity: Necrostatin 2 (also known as Necrostatin-2, Necrostatin-2 racemate, (±)-Necrostatin-2, 7-Cl-O-Nec-1 and Nec-1s, is a potent necroptosis inhibitor with EC50 of 50 nM. It is a racemic mixture that inhibits receptor-interacting protein kinase 1 (RIPK1) autophosphorylation. Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. It can be induced in a FADD-deficient variant of human Jurkat T cells treated with TNF-alpha. Necrostatin 2 was also efficacious in an animal model of ischemic stroke. Necrostatin 2 demonstrated moderate pharmacokinetic characteristics and readily entered the central nervous system upon intravenous administration.


Kinase Assay: Necrostatin 2 (also known as Necrostatin-2, Necrostatin-2 racemate, (±)-Necrostatin-2, 7-Cl-O-Nec-1 and Nec-1s, is a potent necroptosis inhibitor with EC50 of 50 nM


Cell Assay: Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. It can be induced in a FADD-deficient variant of human Jurkat T cells treated with TNF-a. 5-(1H-Indol-3-ylmethyl)-2-thiohydantoins and 5-(1H-indol-3-ylmethyl)hydantoins were found to be potent necroptosis inhibitors (called necrostatins).

In VivoNecrostatin 2 demonstrated moderate pharmacokinetic characteristics and readily entered the central nervous system upon intravenous administration.
Animal model
Formulation & Dosage
References Bioorg Med Chem Lett. 2005 Nov 15;15(22):5039-44; Bioorg Med Chem Lett. 2007 Dec 15;17(24):6836-40.